# US 2021/0079558 A1 · BASEHIT, a high-throughput assay to identify proteins involved in host-microbe interaction

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0079558 A1
- Document ID: US20210079558A1
- Status: Published application
- Kind: A1
- Application number: 16/611,952
- Filed: 2018-05-09
- Published: 2021-03-18
- Earliest claimed: 2017-05-09
- Assignees: Yale University
- Applicants: Yale University
- Inventors: Connor Rosen; Noah Palm; Aaron Ring
- Web page: https://patentgrep.com/patent/US20210079558A1

## CPC

- C12N 15/1037: {Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display}
- C40B 40/02: Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
- C07K 16/12: against material from bacteria
- C07K 16/1267: Gram-positive bacteria
- C07K 16/1278: Bacillus (G)
- C07K 16/1282: Clostridium (G)
- C07K 16/4283: {against an allotypic or isotypic determinant on Ig}
- G01N 33/6845: {Methods of identifying protein-protein interactions in protein mixtures}
- C07K 2317/10: characterized by their source of isolation or production
- C07K 2317/22: from camelids, e.g. camel, llama or dromedary
- C07K 2317/30: characterized by aspects of specificity or valency
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention provides a BASEHIT screening method for identifying proteins that are involved in host-microbe interactions which may function as therapeutic targets.

## Claims

### Claim 1

A method of detecting molecules involved in microbial interactions, the method comprising the steps of:
a) contacting a first population of cells comprising one or more display molecules with a second population of cells comprising cells from at least one microbial species;
b) selecting at least one bound display molecule:microbe complex; and
c) detecting the identity of at least one of a bound display molecule.

### Claim 2 (depends on 1)

The method of claim 1, wherein the first population of cells comprises a population of yeast cells.

### Claim 3 (depends on 1)

The method of claim 1, wherein the display molecule comprises at least one of a protein, a peptide, a fusion protein, an antibody, a nanobody, an affibody, an anticalin, and a monobody.

### Claim 4 (depends on 3)

The method of claim 3, wherein the display molecule comprises a nanobody comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO:10.

### Claim 5 (depends on 1)

The method of claim 1, wherein the at least one display molecule comprises a library of host protein sequences.

### Claim 6 (depends on 1)

The method of claim 1, wherein the microbial species is selected from the group consisting of a commensal microbe of the host species and a pathogenic microbe of the host species.

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The method of claim 1, further comprising identifying the at least one bound display molecule as a therapeutic target.

### Claim 9

A method of detecting a microbe that can interact with at least one target sequence, the method comprising the steps of:
a) contacting a first population of cells comprising at least one display molecule comprising at least one target sequence, with a second population of cells comprising cells from at least one microbial species;
b) selecting at least one bound display molecule:microbe complex; and
c) detecting the identity of the at least one bound microbe.

### Claim 10 (depends on 9)

The method of claim 9, wherein the first population of cells comprises a population of yeast cells.

### Claim 11 (depends on 9)

The method of claim 9, wherein the display molecule comprises at least one of a protein, a peptide, a fusion protein, an antibody, a nanobody, an affibody, an anticalin, and a monobody.

### Claim 12 (depends on 11)

The method of claim 11, wherein the display molecule comprises a nanobody comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO:10.

### Claim 13 (depends on 9)

The method of claim 9, wherein the at least one target sequence comprises a host protein sequence.

### Claim 14 (depends on 9)

The method of claim 9, wherein the at least one microbial species is selected from the group consisting of a commensal microbe of the host species, and a pathogenic microbe of the host species.

### Claim 15

(canceled)

### Claim 16

A method of identifying an agent that can affect microbe interaction with at least one target sequence, the method comprising the steps of:
a) contacting a first population of cells comprising at least one display molecule comprising at least one target sequence, with a second population of cells comprising cells from at least one microbial species in the presence of an agent;
b) evaluating the effect of the candidate agent on microbe interaction with at least one target sequence, wherein the microbial interaction with at least one target sequence is increased or decreased in the presence of the agent; and
c) identifying the agent as a mediator of microbe interaction with the at least one target sequence.

### Claim 17 (depends on 1)

A composition comprising a therapeutic agent targeted to a microbial species, wherein the therapeutic agent comprises a display molecule identified using the method of claim 1.

### Claim 18 (depends on 17)

The composition of claim 17, wherein the therapeutic agent comprises an agent selected from the group consisting of an antibody, a bispecific antibody, a nanobody or fragment thereof.

### Claim 19

(canceled)

### Claim 20 (depends on 18)

The composition of claim 18, wherein the therapeutic agent comprises a bispecific antibody, and further wherein the bispecific antibody targets a microbe and a target sequence, wherein the target sequence is selected from the group consisting of an antibody, an antibody fragment and an antibody mimetic.

### Claim 21 (depends on 20)

The composition of claim 20, wherein the bispecific antibody comprises an IgA antibody.

### Claim 22

(canceled)

### Claim 23 (depends on 18)

The composition of claim 18, wherein the therapeutic agent comprises a nanobody, and further wherein the nanobody comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO:10.

### Claim 24 (depends on 17)

A method of treating a disease or disorder associated with a microbe comprising administering the therapeutic agent of claim 17 to a subject in need thereof.

### Claim 25

(canceled)
